1013 related articles for article (PubMed ID: 18155257)
1. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Vemuri VK; Janero DR; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
[TBL] [Abstract][Full Text] [Related]
2. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.
Janero DR; Makriyannis A
Curr Psychiatry Rep; 2007 Oct; 9(5):365-73. PubMed ID: 17915075
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
Janero DR; Makriyannis A
Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
5. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
Kyrou I; Valsamakis G; Tsigos C
Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoids and Metabolic Disorders.
Gatta-Cherifi B; Cota D
Handb Exp Pharmacol; 2015; 231():367-91. PubMed ID: 26408168
[TBL] [Abstract][Full Text] [Related]
8. Role of the endocannabinoid system in metabolic control.
Wang J; Ueda N
Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):1-10. PubMed ID: 18090663
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Tucci SA; Halford JC; Harrold JA; Kirkham TC
Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoids in appetite control and the treatment of obesity.
Kirkham TC; Tucci SA
CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):272-92. PubMed ID: 16787229
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
Di Marzo V
Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
16. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
Sulcová A
Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
[TBL] [Abstract][Full Text] [Related]
17. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Patti ME
J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid system--a novel target for cardiometabolic risk.
Joshi SR
J Assoc Physicians India; 2007 Jun; 55():439-44. PubMed ID: 17879500
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system--back to the scene of cardiometabolic risk factors control?
Martins CJ; Genelhu V; Di Marzo V; Francischetti EA
Horm Metab Res; 2014 Jul; 46(8):529-36. PubMed ID: 24867141
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
